Resumen de Initial experience with golimumab in clinical practice for ulcerative colitis
Luisa Castro Laria, Federico Argüelles Arias, Valle García Sánchez, José Manuel Benítez Cantero, R. Fernández Pérez, A. Trapero, F. Gallardo Sánchez, Héctor Pallarés Manrique, María Pilar Gómez García, María José Cabello Tapia, Aurora Talavera Fabuel, Ana Bejarano García, Eduardo Leo Carnerero, Álvaro Hernández Martínez, Ángel Caunedo Álvarez, Juan Manuel Herrerías Gutiérrez
Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.
Purpose: To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice.
Methods: Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg.
Results: Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%.
Conclusions: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied.
